[go: up one dir, main page]

PL1802329T3 - Formulacja farmaceutyczna zawierająca krystaliczną insulinę oraz rozpuszczoną insulinę - Google Patents

Formulacja farmaceutyczna zawierająca krystaliczną insulinę oraz rozpuszczoną insulinę

Info

Publication number
PL1802329T3
PL1802329T3 PL05792052T PL05792052T PL1802329T3 PL 1802329 T3 PL1802329 T3 PL 1802329T3 PL 05792052 T PL05792052 T PL 05792052T PL 05792052 T PL05792052 T PL 05792052T PL 1802329 T3 PL1802329 T3 PL 1802329T3
Authority
PL
Poland
Prior art keywords
insulin
pharmaceutical formulation
dissolved
crystalline
crystalline insulin
Prior art date
Application number
PL05792052T
Other languages
English (en)
Inventor
Petter Berglund
Charlotte Hammelev
Lone Eskildsen
Johanne Madsen
Helle Aalund Olsen
Lone Løgstrup Kimer
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35428106&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1802329(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of PL1802329T3 publication Critical patent/PL1802329T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05792052T 2004-10-05 2005-10-05 Formulacja farmaceutyczna zawierająca krystaliczną insulinę oraz rozpuszczoną insulinę PL1802329T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200401519 2004-10-05
EP20050792052 EP1802329B1 (en) 2004-10-05 2005-10-05 A pharmaceutical formulation comprising crystalline insulin and dissolved insulin
PCT/EP2005/055017 WO2006037789A1 (en) 2004-10-05 2005-10-05 A pharmaceutical formulation comprising crystalline insulin and dissolved insulin

Publications (1)

Publication Number Publication Date
PL1802329T3 true PL1802329T3 (pl) 2015-10-30

Family

ID=35428106

Family Applications (2)

Application Number Title Priority Date Filing Date
PL05792052T PL1802329T3 (pl) 2004-10-05 2005-10-05 Formulacja farmaceutyczna zawierająca krystaliczną insulinę oraz rozpuszczoną insulinę
PL15161696T PL2918286T3 (pl) 2004-10-05 2005-10-05 Preparat farmaceutyczny zawierający insulinę w postaci krystalicznej, jak również w formie rozpuszczonej

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL15161696T PL2918286T3 (pl) 2004-10-05 2005-10-05 Preparat farmaceutyczny zawierający insulinę w postaci krystalicznej, jak również w formie rozpuszczonej

Country Status (19)

Country Link
US (1) US7884181B2 (pl)
EP (4) EP1802329B1 (pl)
JP (1) JP5080259B2 (pl)
KR (1) KR101238184B1 (pl)
CN (2) CN102772788B (pl)
AU (1) AU2005291233B2 (pl)
BR (1) BRPI0516464B8 (pl)
CA (1) CA2581798A1 (pl)
CY (1) CY1124650T1 (pl)
DK (1) DK2918286T3 (pl)
ES (3) ES2544329T3 (pl)
HU (1) HUE048806T2 (pl)
LT (1) LT2918286T (pl)
MX (1) MX2007003897A (pl)
PL (2) PL1802329T3 (pl)
PT (1) PT2918286T (pl)
RU (1) RU2389503C2 (pl)
SI (1) SI2918286T1 (pl)
WO (1) WO2006037789A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008065138A1 (en) * 2006-11-29 2008-06-05 Novo Nordisk A/S Novel insulin crystal and method for preparing the crystal
CN102219851B (zh) * 2011-05-09 2012-05-30 甘李药业有限公司 甘精胰岛素结晶的制备方法
RU2015130613A (ru) * 2012-12-26 2017-01-31 Вокхардт Лимитед Фармацевтическая композиция
JP6641280B2 (ja) 2014-01-09 2020-02-05 サノフイSanofi インスリンアナログおよび/またはインスリン誘導体の安定化された医薬製剤
RU2014120626A (ru) * 2014-05-22 2015-11-27 Владимир Андреевич Сабецкий Инсулинсодержащий препарат пролонгированного действия
CN105535942B (zh) * 2016-01-28 2017-07-28 通化东宝药业股份有限公司 一种赖脯胰岛素硫酸鱼精蛋白制剂的制备方法及其制备的赖脯胰岛素硫酸鱼精蛋白制剂
WO2017163159A1 (en) * 2016-03-21 2017-09-28 Wockhardt Limited Biphasic pharmaceutical composition of insulin human
CN113248591B (zh) * 2021-07-08 2021-09-28 北京惠之衡生物科技有限公司 一种门冬胰岛素结晶工艺
CN113384529B (zh) * 2021-07-08 2021-11-26 北京惠之衡生物科技有限公司 一种门冬胰岛素注射液及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB889769A (en) * 1957-07-18 1962-02-21 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
ES2292189T3 (es) * 1996-06-20 2008-03-01 Novo Nordisk A/S Preparaciones a base de insulina conteniendo manitol.
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
HU228094B1 (en) 1996-06-20 2012-10-29 Novo Nordisk As Insulin preparations containing nacl
CA2468100A1 (en) * 2001-12-20 2003-07-03 Eli Lilly And Company Insulin molecule having protracted time action
JP2006519791A (ja) * 2003-03-13 2006-08-31 ノボ ノルディスク アクティーゼルスカブ 新規なnphインスリン製剤

Also Published As

Publication number Publication date
JP5080259B2 (ja) 2012-11-21
EP2926828A1 (en) 2015-10-07
EP3689366A1 (en) 2020-08-05
BRPI0516464A (pt) 2008-09-09
RU2389503C2 (ru) 2010-05-20
MX2007003897A (es) 2007-05-21
RU2007111879A (ru) 2008-11-20
SI2918286T1 (sl) 2020-06-30
LT2918286T (lt) 2020-04-10
CN102772788B (zh) 2017-06-06
PL2918286T3 (pl) 2020-06-29
EP2926828B1 (en) 2019-12-11
KR20070100874A (ko) 2007-10-12
BRPI0516464B8 (pt) 2021-05-25
CA2581798A1 (en) 2006-04-13
CY1124650T1 (el) 2022-03-24
HUE048806T2 (hu) 2020-08-28
EP2918286B1 (en) 2020-03-18
KR101238184B1 (ko) 2013-03-04
CN101035557B (zh) 2012-09-05
ES2544329T3 (es) 2015-08-28
WO2006037789A1 (en) 2006-04-13
PT2918286T (pt) 2020-03-27
CN102772788A (zh) 2012-11-14
EP1802329A1 (en) 2007-07-04
CN101035557A (zh) 2007-09-12
JP2008515853A (ja) 2008-05-15
EP2918286A1 (en) 2015-09-16
AU2005291233B2 (en) 2011-02-03
US20080171694A1 (en) 2008-07-17
EP1802329B1 (en) 2015-05-06
ES2774354T3 (es) 2020-07-20
ES2779957T3 (es) 2020-08-20
DK2918286T3 (da) 2020-03-30
US7884181B2 (en) 2011-02-08
BRPI0516464B1 (pt) 2016-11-08
AU2005291233A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
EP1898922A4 (en) MEDICINE OR IMPROVED PHARMACEUTICAL COMPOUNDS AND PREPARATION THEREOF
GB0413730D0 (en) A pharmaceutical composition and its use
IL179795A0 (en) A pharmaceutical composition and its use
EP1887008A4 (en) THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICAL APPLICATION THEREOF
EP1802258A4 (en) BIOSYNCHRONE TRANSDERMAL MEDICINES
IL177869A0 (en) A stable pharmaceutical composition comprising an acid labile drug
GB0403247D0 (en) A pharmaceutical composition
IL185390A0 (en) A solid pharmaceutical dosage formulation
PL3437682T3 (pl) Urządzenie do podawania leków
GB0402736D0 (en) A drug delivery device
SI1957073T1 (sl) Medicinsko zdravilo
IL183503A0 (en) Device for injecting a pharmaceutical active principle
IL183929A0 (en) Use of inerferon - ?? in the preparation of a medicament
EP1781355A4 (en) DEVICE FOR DELIVERY OF DRUGS
PT3056492T (pt) Sal de meglumina e formas cristalinas do mesmo de um fármaco (delafloxacina)
IL184008A0 (en) 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments
PL1802329T3 (pl) Formulacja farmaceutyczna zawierająca krystaliczną insulinę oraz rozpuszczoną insulinę
ZA200700511B (en) A pharmaceutical composition comprising gabapentin
HK1105358A1 (en) Solid pharmaceutical formulation
GB0400452D0 (en) A pharmaceutical composition
IL176762A0 (en) Pharmaceutical compositions comprising growth hormone and a statin
ZA200705080B (en) Aminocarboxylic acid derivative and medicinal use thereof
GB0406048D0 (en) Drug formulations
GB0613761D0 (en) A pharmaceutical formulation and method for the preparation thereof
ZA200704650B (en) 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments